Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
USA Rare Earth Q1 2026 Earnings Call - Securing Western Supply Chains With $3.6B Brazil Deal And $1.6B Government Funding
USA Rare Earth is pivoting from a development-stage project to a fully integrated global rare earth platform. The company announced three critical transactions: the acquisition of Serra Verde Group fo...
- Acquisition of Serra Verde Group for $3.64 billion secures the Pela Ema mine in Brazil, the only scaled producer of all four magnetic rare earths outside of Asia.
- Serra Verde includes a 15-year offtake agreement with a U.S. government-financed SPV featuring price floors for NdPr, dysprosium, and terbium, providing transparent price signals.
- Strategic investment in Carester amplifies global leadership in heavy rare earth processing and grants access to world-class engineering capabilities and IP.
- +11 more takeaways
Energous Wireless Power Solutions Q1 2026 Earnings Call - Fortune 10 Deployments Drive Revenue Surge and Margin Expansion
Energous Wireless Power Solutions reported a 51% year-over-year improvement in net loss for Q1 2026, with revenue jumping to $3.1 million from $0.3 million in the prior year period. The company highli...
- Revenue surged to $3.1 million in Q1 2026, up 933% year-over-year from $0.3 million, marking the fifth consecutive quarter of revenue growth.
- Net loss improved 51% year-over-year to $1.7 million, from $3.4 million in Q1 2025, as gross margin expanded to 36% from 27%.
- Gross margin expansion was driven by higher volume shipments of the PowerBridge Pro transmitter, which has achieved zero returns since commercial production began in 2024.
- +7 more takeaways
Omeros Corporation Q1 2026 Earnings Call - YARTEMLEA Launch Drives Strong Early Uptake and Cash Flow Positivity
Omeros Corporation delivered a robust first quarter 2026, driven by the successful launch of YARTEMLEA, the first and only approved treatment for TA-TMA. The company reported $11.1 million in gross re...
- YARTEMLEA launched in mid-January 2026, generating $11.1 million in gross revenues and $9.9 million in net revenues in Q1 2026, with gross-to-net adjustments held to a modest 11%.
- The company achieved cash flow positivity in the first quarter, just weeks after launch, and projects company-wide positive cash flow within 18 months.
- Adoption is accelerating ahead of plan: 30 unique accounts ordered YARTEMLEA by March 31, with 60% of the top 10 U.S. transplant centers securing P&T committee approvals.
- +7 more takeaways
HeartBeam Q1 2026 Earnings Call - Lean Commercial Rollout and Cash Runway Extended
HeartBeam is executing a capital-efficient, lean commercial rollout of its cable-free synthesized 12-lead ECG, securing anchor accounts in four key U.S. markets and validating a premium subscription m...
- HeartBeam secured its first commercial partnership with ClearCardio, establishing a presence in New York City, Dallas, and South Florida, and later added Atelier Health in Beverly Hills to cover Southern California.
- The company’s premium subscription model is priced between $750 and $1,000 annually, with early physician feedback indicating strong demand for the clinical-grade 12-lead ECG capability.
- HeartBeam is executing a lean commercial strategy, using a small team to validate the business model in four key geographies before scaling sales and clinical support in the second half of 2026.
- +7 more takeaways
Marchex Q1 2026 Earnings Call - Archenia Acquisition and AI Bundling Drive EBITDA Upgrade
Marchex reported a slight sequential revenue decline to $10.6 million in Q1 2026, but management pivoted sharply toward a higher-growth narrative centered on its pending Archenia acquisition and AI-dr...
- Revenue dipped slightly to $10.6 million in Q1 2026, down from $10.8 million in Q4 2025, due to legacy platform migration offsets partially masked by new sales and upsells.
- Management announced a significant EBITDA upgrade, guiding Q2 adjusted EBITDA to $1.6–$1.8 million, up from prior guidance of >$1 million.
- Standalone Q3 2026 adjusted EBITDA is now projected at $2 million or more, with combined Archenia EBITDA potentially reaching $2.5 million if the deal closes.
- +7 more takeaways
CytoSorbents Q1 2026 Earnings Call - DrugSorb-ATR FDA Pathway Clarified Amidst Geopolitical Headwinds
CytoSorbents reported a 2% year-over-year revenue increase to $8.9 million in Q1 2026, driven by strong 13% growth in direct international sales outside Germany, which was partially offset by a declin...
- Q1 2026 revenue reached $8.9 million, marking a 2% year-over-year increase, though this was down 7% on a constant currency basis.
- Direct international sales outside Germany grew 13% year-over-year, highlighting improved physician awareness and execution in new markets.
- German market sales declined year-over-year, but management reports improved sales force productivity and plans to selectively rebuild the team to drive future growth.
- +11 more takeaways
Journey Medical Q1 2026 Earnings Call - EMROSI Revenues Jump 21% as Reimbursement Wins Fuel Operating Leverage
Journey Medical delivered a strong first quarter with total revenues reaching $16 million, driven by a 200% year-over-year surge in EMROSI sales to $6.3 million. The company reported its third consecu...
- EMROSI revenues surged 200% year-over-year to $6.3 million, contributing to total net product revenue growth of 21% to $16 million.
- The company achieved positive adjusted EBITDA of $600,000 for the third consecutive quarter, reflecting improving operating leverage.
- Cash reserves increased to $27.2 million by quarter end, up from $24.1 million in December 2025.
- +7 more takeaways
Aytu Biopharma Q3 FY2026 Earnings Call - EXXUA Launch Accelerates With 26% Monthly Script Growth
Aytu Biopharma's first full commercial quarter for EXXUA, its novel antidepressant, delivered a 26% month-over-month script growth rate, climbing from 200 prescriptions in January to over 900 in April...
- EXXUA script volume surged 26% month-over-month in April, reaching over 920 prescriptions, up from 700 in March, signaling accelerating physician adoption.
- More than 1,300 prescriptions were written in Q3 by over 450 unique prescribers, representing 10-13% of the initial 3,500-4,000 targeted physician universe.
- EXXUA generated $2.4 million in net revenue for Q3, exceeding management's initial launch expectations and demonstrating strong early commercial traction.
- +7 more takeaways
Usio Q1 FY2026 Earnings Call - Record Revenue Growth Driven by PayFac and Real-Time Payments Momentum
Usio delivered a record first quarter for fiscal 2026, posting 16% year-over-year revenue growth to reach an all-time high. The company achieved positive GAAP net income, adjusted EBITDA, and operatin...
- Usio reported record quarterly revenue of $38.5 million (implied by 16% growth context), representing a 16% year-over-year increase and a new all-time high for the company.
- The company achieved positive GAAP net income of approximately $130,000, along with positive adjusted EBITDA and operating cash flow, signaling a successful transition to sustainable profitability.
- Card processing revenue surged 23% year-over-year to $9.7 million, driven primarily by the PayFac segment which now constitutes 78% of card revenues and is growing at a rate exceeding 20%.
- +9 more takeaways
Longeveron Q1 2026 Earnings Call - FDA Drops Pivotal Status for HLHS Trial, Shifts to Asset-Light Partnership Model
Longeveron is pivoting to an asset-light, partnership-driven strategy as it prepares for a critical regulatory juncture. The FDA has withdrawn pivotal status from the ELPIS II trial for laromestrocel ...
- CEO Stephen Willard completed a strategic review in February, transitioning Longeveron to an asset-light model focused on licensing partnerships for laromestrocel across all four development programs.
- The FDA withdrew pivotal status from the ELPIS II trial in hypoplastic left heart syndrome (HLHS), rejecting right ventricle ejection fraction (RVEF) as a valid primary efficacy endpoint.
- Management plans to submit a revised statistical analysis plan (SAP) to the FDA post-August 2026 data readout, focusing on composite endpoints like all-cause mortality and cardiac transplant-free survival.
- +7 more takeaways